Biolab has changes to its Advisory Board
As part of its strategic restructuring to drive sustainable growth, the Biolab Pharmaceuticals announces changes to the Advisory Board.
CEO Fabio Amorosino takes over as interim chairman of the board, which also includes founding partners Cleiton Castro Marques, Dante Alario and Paulo Castro Marques. In addition, three new independent directors have been brought in to bring perspectives and experiences that will strengthen the future of the organization.
The professionals
Cassio Casseb joins the Board to bring his expertise in the financial and business sectors. He has worked in important organizations and strategic leadership roles, such as president of Banco do Brasil, Grupo Pão de Açúcar and Coinbra (Dreyfus Group), among others. Cassio will bring his vision of governance and his commitment to significant results to Biolab. "I am honored to be part of a company that combines innovation and purpose, and I hope to add my experience to Biolab's success," he said.
João Bezerra Leite, former CTO (Chief Technology Officer) at Itaú Unibanco, has a relevant background in technology and innovation and joined the board in November with the aim of boosting Biolab's progress in the digital age. "I am very pleased to be part of projects with purpose and impact like Biolab, in an environment with solid values and surrounded by people who want to transform and from whom I can learn," says João Bezerra.
Paulo Gandolfi, the current CEO of 3M Brazil, brings to the board his vast experience in Research, Development and Innovation (RD&I), aligned with the strategies of various units in the business. His ability to lead multifunctional operations and integrate global strategies will be essential to increasing Biolab's leading role in the health sector. "It's a privilege to contribute to a company recognized for its focus on RD&I and commitment to excellence," says Gandolfi.
With a strengthened Advisory Board, Biolab reaffirms its commitment to innovation, sustainability and the creation of value for the healthcare market, maintaining its position as a benchmark in the sector.